Status: Recruiting
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-49Biological sex: FemaleType: InterventionalSponsor: BlueSky Immunotherapies GmbHUpdated: Feb 14, 2025Locations: 1
Eligibility criteria
Females, 18-49 years of age with HPV16 infection and cervical cytological evalua... [+7]
Any vaccination within 6 weeks of day 0 [+20]